 |
23 Diseases |  |
176 Trials |
|
176 Trials |  |
4873 News |  |
| «12...50515253545556575859606162» |
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Combination therapy: GO29365: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 24, 2017
P1/2, N=225, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion, Phase classification: An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 16, 2017
P2, N=20, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Approved for marketing --> Completed | Phase classification: P4 --> P2
- ||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial, Combination therapy: PrE0403: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (clinicaltrials.gov) - Apr 13, 2017
P2, N=56, Not yet recruiting, Sponsor: PrECOG, LLC.
- | Gazyva (obinutuzumab) / Roche, Biogen
Clinical: Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome (clinicaltrials.gov) - Apr 13, 2017
P1, N=10, Not yet recruiting, Sponsor: University of California, San Diego
- ||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed: A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Apr 7, 2017
P1/2, N=59, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Approved for marketing --> Completed | Phase classification: P4 --> P2 Recruiting --> Active, not recruiting
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: GIBB: A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Apr 6, 2017
P2, N=102, Active, not recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2019 --> Nov 2016
- avadomide (CC-122) / BMS
Combination therapy: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (clinicaltrials.gov) - Apr 4, 2017
P1b, N=48, Recruiting, Sponsor: Celgene
Trial primary completion date: Aug 2019 --> Nov 2016 N=38 --> 48
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, iladatuzumab vedotin (DCDS0780A) / Roche, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 31, 2017
P1, N=98, Recruiting, Sponsor: Hoffmann-La Roche
N=38 --> 48 Trial primary completion date: Oct 2018 --> Sep 2019
- | Phase classification, Combination therapy: GO29833: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Mar 29, 2017
P1/2, N=134, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2018 --> Sep 2019 Phase classification: P1 --> P1/2
- | Gazyva (obinutuzumab) / Roche, Biogen, entospletinib (GS-9973) / Kronos Bio
Trial initiation date, Combination therapy: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 27, 2017
P1/2, N=29, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
Phase classification: P1 --> P1/2 Initiation date: Mar 2017 --> Jun 2017
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial, Post-transplantation: Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) (clinicaltrials.gov) - Mar 22, 2017
P2, N=0, Withdrawn, Sponsor: Case Comprehensive Cancer Center
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Mar 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- || Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date, Combination therapy: A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Mar 20, 2017
P1, N=100, Recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> Jul 2020
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change, Trial initiation date, Trial termination, Trial primary completion date: FIL-GALILEO: Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. (clinicaltrials.gov) - Mar 20, 2017
P2, N=1, Terminated, Sponsor: Fondazione Italiana Linfomi ONLUS
Trial primary completion date: Nov 2016 --> Jul 2020 N=90 --> 1 | Initiation date: Jun 2016 --> Sep 2016 | Recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Feb 2017; GA101-CHOP not advantage from rituximab-CHOP
- | Gazyva (obinutuzumab) / Roche, Biogen
Trial initiation date: Lenalidomide and Obinutuzumab for Previously Untreated CLL (clinicaltrials.gov) - Mar 15, 2017
P2, N=25, Not yet recruiting, Sponsor: University of California, San Diego
N=90 --> 1 | Initiation date: Jun 2016 --> Sep 2016 | Recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Feb 2017; GA101-CHOP not advantage from rituximab-CHOP Initiation date: Jun 2017 --> Dec 2017
- | idasanutlin (RG7388) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Phase classification, Combination therapy: A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants (clinicaltrials.gov) - Mar 13, 2017
P1/2, N=120, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jun 2017 --> Dec 2017 Phase classification: P1 --> P1/2
- || Trial primary completion date, Combination therapy: Phase 1b Safety and Efficacy Study of TRU-016 (clinicaltrials.gov) - Mar 10, 2017
P1b, N=123, Recruiting, Sponsor: Aptevo Therapeutics
Phase classification: P1 --> P1/2 Trial primary completion date: Dec 2016 --> Jun 2018
- | Gazyva (obinutuzumab) / Roche, Biogen, Zydelig (idelalisib) / Gilead
Enrollment open, Trial primary completion date: RemodelWM3: Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Mar 9, 2017
P2, N=50, Recruiting, Sponsor: French Innovative Leukemia Organisation
Trial primary completion date: Dec 2016 --> Jun 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Mar 2019
- ||| Columvi (glofitamab-gxbm) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P1 trial, Combination therapy: NP30179: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 9, 2017
P1, N=140, Recruiting, Sponsor: Hoffmann-La Roche
- ||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 3, 2017
P1, N=60, Recruiting, Sponsor: Beth Christian
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Mar 2019 Not yet recruiting --> Recruiting
- || Copiktra (duvelisib) / Secura Bio, Yakult Honsha
Trial primary completion date, Combination therapy: A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) (clinicaltrials.gov) - Feb 23, 2017
P1b/2, N=120, Active, not recruiting, Sponsor: Verastem, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2017 --> Jan 2017
- || Gazyva (obinutuzumab) / Roche, Biogen
Clinical: NOBILITY: A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) (clinicaltrials.gov) - Feb 23, 2017
P2, N=120, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jul 2017 --> Jan 2017 Trial primary completion date: Aug 2017 --> Aug 2019
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New trial, Observational data: Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=50, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Enrollment change: A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Feb 23, 2017
P1, N=92, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2017 --> Aug 2019 N=46 --> 92
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Trial initiation date, Combination therapy: SAKK 35/15: Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients (clinicaltrials.gov) - Feb 20, 2017
P1, N=25, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
N=46 --> 92 Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Feb 2017
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche, Tecentriq (atezolizumab) / Roche
Phase classification, Combination therapy: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 17, 2017
P1, N=92, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Feb 2017 Phase classification: P1b --> P1
- ||||| Calquence (acalabrutinib) / AstraZeneca
Enrollment closed, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Feb 16, 2017
P3, N=535, Active, not recruiting, Sponsor: Acerta Pharma BV
Phase classification: P1b --> P1 Recruiting --> Active, not recruiting
- |||| Velexbru (tirabrutinib) / Ono Pharma, Gilead, entospletinib (GS-9973) / Kronos Bio
Enrollment open: Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 15, 2017
P2, N=60, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Enrollment change, Combination therapy: A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 11, 2017
P1/2, N=85, Active, not recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=110 --> 85
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, iladatuzumab vedotin (DCDS0780A) / Roche, Rituxan (rituximab) / Roche
Enrollment change, Combination therapy: A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 10, 2017
P1, N=98, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=110 --> 85 N=80 --> 98
- | Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, bendamustine / Generic mfg.
Journal: Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. (Pubmed Central) - Feb 2, 2017
Results were similar when follicular lymphoma patients were analyzed separately. The delayed time to worsening and greater proportion of patients reporting meaningful improvement in HRQoL in the G-B arm suggest that benefit in PFS is not at the expense of an increase in treatment-related toxicity that could lead to reduced HRQoL.
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome (clinicaltrials.gov) - Feb 2, 2017
P2, N=72, Recruiting, Sponsor: M.D. Anderson Cancer Center
The delayed time to worsening and greater proportion of patients reporting meaningful improvement in HRQoL in the G-B arm suggest that benefit in PFS is not at the expense of an increase in treatment-related toxicity that could lead to reduced HRQoL. Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Jan 2017 | Trial primary completion date: Oct 2020 --> Jan 2021
- ||| Enrollment closed, Combination therapy: ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov) - Feb 1, 2017
P2, N=246, Active, not recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Jan 2017 | Trial primary completion date: Oct 2020 --> Jan 2021 Recruiting --> Active, not recruiting
- | parsaclisib (INCB50465) / Incyte
New P1 trial, Combination therapy: Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) (clinicaltrials.gov) - Feb 1, 2017
P1, N=45, Not yet recruiting, Sponsor: Incyte Corporation
- || Velexbru (tirabrutinib) / Ono Pharma, Gilead
Trial primary completion date, Combination therapy: Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies (clinicaltrials.gov) - Jan 30, 2017
P1b, N=368, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2018 --> Jan 2018
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed: GIBB: A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 18, 2017
P2, N=102, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Dec 2018 --> Jan 2018 Recruiting --> Active, not recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: ICLL-07: Phase II Trial GA101 Inbrutinib B CLL (clinicaltrials.gov) - Jan 18, 2017
P2, N=12, Recruiting, Sponsor: French Innovative Leukemia Organisation
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment change, Trial primary completion date: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma (clinicaltrials.gov) - Jan 10, 2017
P1/2, N=315, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Trial primary completion date: Dec 2016 --> Dec 2017 N=200 --> 315 | Trial primary completion date: Dec 2016 --> Dec 2017
- |||| Velexbru (tirabrutinib) / Ono Pharma, Gilead, Zydelig (idelalisib) / Gilead
Enrollment open: Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 5, 2017
P2, N=60, Recruiting, Sponsor: Gilead Sciences
N=200 --> 315 | Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, entospletinib (GS-9973) / Kronos Bio
New P1/2 trial, Combination therapy: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 5, 2017
P1/2, N=29, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- Copiktra (duvelisib) / Secura Bio, Yakult Honsha
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) (clinicaltrials.gov) - Dec 27, 2016
P1b, N=3, Terminated, Sponsor: Infinity Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting N=46 --> 3 | Recruiting --> Terminated | Trial primary completion date: Nov 2021 --> Nov 2016; The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.
- avadomide (CC-122) / BMS
Combination therapy: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (clinicaltrials.gov) - Dec 23, 2016
P1b, N=38, Recruiting, Sponsor: Celgene Corporation
N=46 --> 3 | Recruiting --> Terminated | Trial primary completion date: Nov 2021 --> Nov 2016; The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib. Trial primary completion date: Oct 2017 --> Jul 2018
- Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P1 trial: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 14, 2016
P1, N=60, Not yet recruiting, Sponsor: Beth Christian
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial: Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL (clinicaltrials.gov) - Dec 9, 2016
P2, N=21, Not yet recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma (clinicaltrials.gov) - Dec 7, 2016
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2017 --> Jul 2018 Not yet recruiting --> Recruiting
- ||||| Velexbru (tirabrutinib) / Ono Pharma, Gilead, entospletinib (GS-9973) / Kronos Bio
New P2 trial: Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Dec 6, 2016
P2, N=60, Not yet recruiting, Sponsor: Gilead Sciences
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: FIL-GALILEO: Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. (clinicaltrials.gov) - Dec 6, 2016
P2, N=90, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Calquence (acalabrutinib) / AstraZeneca
Phase classification, Combination therapy: ACE-CL-003: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL (clinicaltrials.gov) - Dec 5, 2016
P1b, N=45, Active, not recruiting, Sponsor: Acerta Pharma BV
Not yet recruiting --> Recruiting Phase classification: P1 --> P1b
- | Enrollment open, IO biomarker: GAIA: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation (clinicaltrials.gov) - Nov 29, 2016
P3, N=920, Recruiting, Sponsor: German CLL Study Group
Phase classification: P1 --> P1b Not yet recruiting --> Recruiting
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response (clinicaltrials.gov) - Nov 29, 2016
P2, N=120, Recruiting, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jul 2016 | Not yet recruiting --> Recruiting